Deals
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
FEATURED STORIES
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
While merger and acquisition activity has been robust of late, frequent changes in guidance and leadership at the regulator add risk to any transaction.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biotechnology firm Ginkgo Bioworks is going public via a merger with Soaring Eagle Acquisition Corp.
AbbVie’s Allergan Aesthetics’ most well-known brands right now include BOTOX and CoolSculpting, among others. However, with the company’s latest acquisition, another one might slide its way to the top.
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
Two new notable biotech/biopharma acquisitions were reported this week: Athenex has acquired Kuur Therapeutics, while Altasciences has acquired preclinical CRO Calvert Laboratories.
Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.
Two weeks after announcing plans for initial public offerings, Gyroscope Therapeutics and Talaris Therapeutics have now set the terms for their debut on the Nasdaq.
Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC). Once the deal is closed, outstanding shares and warrants of MAAC will be traded for newly issued shares and warrants of the company.
After quietly filing plans for an initial public offering earlier this month, U.K.-based Vaccitech raised $110.5 million in its IPO.
Pfizer is expanding its presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and its lead antifungal compound Fosmanogepix.
Special Purpose Acquisition Companies (SPACs) are here to stay, offering one more way for companies to access public markets. But doing so isn’t a quick snap of the fingers.